Surgical site infections (SSIs) remain a persistent complication following hysterectomy, contributing to increased morbidity, prolonged hospital stays, and elevated healthcare costs. A recent internal audit from a large tertiary hospital demonstrated a substantial decrease in hysterectomy-related SSIs after the introduction of metronidazole as part of the prophylactic antibiotic regimen.
Hysterectomy, a common gynaecological procedure, carries an inherent risk of surgical site infection. These infections can manifest as superficial incisional, deep incisional, or organ/space infections, each with varying degrees of clinical impact. The aetiology of SSIs following hysterectomy often involves polymicrobial flora, including both aerobic and anaerobic bacteria from the vaginal and gastrointestinal tracts. Standard prophylactic antibiotic regimens typically target common aerobic pathogens, but the role of anaerobic coverage has been a subject of ongoing evaluation in clinical practice.
The Hospital Audit
An internal audit was conducted at a large tertiary care hospital to assess the impact of a revised prophylactic antibiotic protocol for patients undergoing hysterectomy. The audit period spanned 24 months, with 12 months preceding and 12 months following the protocol change. Prior to the intervention, the standard prophylactic regimen consisted of a single dose of a first-generation cephalosporin. The revised protocol introduced a single intravenous dose of metronidazole (500 mg) administered concurrently with the cephalosporin, 30 to 60 minutes before surgical incision. The audit included all patients undergoing abdominal, vaginal, and laparoscopic hysterectomies during the specified periods. Data collected included patient demographics, surgical approach, duration of surgery, and the occurrence of SSIs within 30 days post-procedure, as defined by Centers for Disease Control and Prevention (CDC) criteria.
A total of 1,250 hysterectomies were performed during the pre-intervention period, and 1,310 hysterectomies were performed during the post-intervention period. The patient populations in both periods were comparable regarding age, body mass index, and comorbidities. The overall SSI rate in the pre-intervention group was 4.8% (60 cases out of 1,250). Following the implementation of the revised protocol, the overall SSI rate decreased to 1.2% (16 cases out of 1,310). This represented a statistically significant reduction (p < 0.001). Specifically, the reduction was observed across all types of SSIs, with a notable decrease in organ/space infections. The audit did not report any significant increase in adverse drug reactions attributable to the addition of metronidazole. The hospital's infection control committee reviewed the data and confirmed the observed trend.
The audit's limitations include its retrospective, single-centre design, which may limit generalisability. The absence of a randomised control group means that other concurrent infection control initiatives, though not explicitly identified, cannot be entirely ruled out as contributing factors. However, the consistent methodology for SSI surveillance and the clear temporal association between the protocol change and the decline in infection rates provide compelling evidence. Future prospective, multi-centre studies would be beneficial to further validate these findings and explore optimal dosing and duration of anaerobic prophylaxis in various surgical contexts.
The data from this hospital audit offers a straightforward, actionable insight for gynaecological surgeons and hospital formulary committees. The observed reduction in hysterectomy SSIs with the addition of metronidazole is not a novel concept, but it serves as a potent reminder of the importance of comprehensive antimicrobial prophylaxis. For too long, the focus has often been solely on aerobic coverage, potentially overlooking the significant contribution of anaerobic bacteria to post-surgical infections in procedures involving the lower genital tract and bowel.
Clinicians should critically evaluate their current prophylactic antibiotic guidelines for hysterectomy. If anaerobic coverage is not routinely included, this audit provides a strong impetus for its consideration. The cost-effectiveness of preventing SSIs, which can lead to extended hospital stays, re-admissions, and additional treatment, far outweighs the minimal cost associated with a single dose of generic metronidazole. This is not about introducing a new, expensive drug, but rather optimising the use of an established, affordable agent.
From an industry perspective, this highlights that sometimes the most impactful interventions are not found in novel drug development, but in the intelligent application of existing pharmacotherapy. Guideline bodies, such as the American College of Obstetricians and Gynecologists (ACOG) and the National Institute for Health and Care Excellence (NICE), already provide recommendations for prophylactic antibiotics in gynaecological surgery. This audit reinforces the rationale behind including anaerobic coverage in these recommendations, particularly for procedures with higher risks of polymicrobial contamination. Patients, ultimately, benefit from reduced complications, faster recovery, and a lower burden of post-operative morbidity.
- The Pivot The addition of metronidazole to standard prophylactic antibiotics for hysterectomy procedures.
- The Data A reduction in SSI rates from 4.8% to 1.2% (p < 0.001) post-intervention.
- The Action Clinicians should review current prophylactic antibiotic protocols for hysterectomy to include anaerobic coverage where not already present.
ART-2026-390
06/26
Cite This Article
Team TLSFE. Metronidazole reduces hysterectomy ssis in hospital audit. The Life Science Feed. Updated June 17, 2026. Accessed June 17, 2026. https://thelifesciencefeed.com/obstetrics-and-gyn/endometriosis/news/metronidazole-reduces-hysterectomy-ssis-in-hospital-audit.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Medical Disclaimer
The information provided on The Life Science Feed is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider regarding any medical condition or treatment decision. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
